The invention relates to compositions and methods for treating an activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL). Specifically, the invention relates to treating ABC-DLBCL by administering an NF-κB Essential Modulator (NEMO) Binding Domain (NBD) peptide or a mimetic thereof that inhibits NF-κB activation.